Ivana Casaroli

Monza, 20900, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.

The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial.

Journal: Leukemia
Published: March 04, 2025

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients.

Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients.

Journal: HemaSphere
Published: November 19, 2024

Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases.

Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases.

Journal: Human pathology
Published: June 04, 2024

Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162.

Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162.

Journal: Journal of clinical medicine
Published: March 02, 2023

Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma.

Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical medicine
Published: October 22, 2022

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.

Journal: Blood
Published: October 29, 2021

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.

Journal: The Lancet. Haematology
Published: August 13, 2020

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.

Journal: Investigational new drugs
Published: February 24, 2019

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.

Journal: British journal of haematology
Published: December 02, 2017

Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.

Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.

Journal: Clinical lymphoma, myeloma & leukemia
Published: June 26, 2014
Showing 1-10 of 10

Last Updated: 09/26/2026